In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, in most cases, responded to it with tumor shrinkage. NF1 affects 1 in 3,000 people. The study results appeared Dec. 29, 2016, in the New England Journal of Medicine [1].
Brain Imaging in Children with Neurological Disorders Links Language Delay to Chromosome Deletion
A study team of radiologists and psychologists has found that children born with DNA copy number deletions in a specific region on chromosome 16 previously linked to neurodevelopmental problems show measurable delays in processing sound and language [1].
![child-in-meg-machine.png Child in a MEG machine](https://www.highlighthealth.com/wp-content/uploads/2015/02/child-in-meg-machine.png)
Better Sleep Linked to Higher Levels of Omega-3 in Diet
New research from the University of Oxford suggests that higher levels of omega-3 fatty acid — primarily found in certain fish such sat tuna and salmon — are associated with better sleep in children. The study is published in the Journal of Sleep Research [1].
![dha-omega-3-fatty-acid.jpg DHA Omega 3 Fatty Acid](https://www.highlighthealth.com/wp-content/uploads/2014/03/dha-omega-3-fatty-acid.jpg)
Using Genomics for Safer, Personalized Medicine Choices for Kids
A new research study at Boston Children’s Hospital, in partnership with the Medical College of Wisconsin (MCW) and the Children’s Hospital of Wisconsin Research Institute, is using genetic information to predict children’s reactions to medications. The goal is to enable clinicians to select a more personalized therapy for each patient.
![personalized-medicine-for-kids.jpg Personalized medicine for kids](https://www.highlighthealth.com/wp-content/uploads/2014/03/personalized-medicine-for-kids.jpg)